ZEDRA
7.1.2020 09:02:07 CET | Business Wire | Press release
ZEDRA Group (“ZEDRA”), the global specialist in Corporate, Fund and ‘Active-Wealth’ services and Corsair Capital LLC (“Corsair”), one of the leading private equity firms focused on the financial and business services industries, today announced the successful close of Corsair’s majority investment in ZEDRA Group. The transaction, which was first announced on November 28, 2018, has been approved by all relevant regulatory authorities.
Following the close of the transaction, Bart Deconinck, a highly experienced industry figure who previously has been CEO of Intertrust and was a founder of Vistra before going on to co found Zedra four years ago, has been appointed Group Executive Chairman. In addition, Ivo Hemelraad, formerly Zedra Group Director Corporate Funds & Legal, will assume the role of Group Chief Executive Officer.
ZEDRA delivers tailored high quality diversified active-wealth solutions to its clients, which include high net worth individuals and their families, as well as medium to large sized companies, asset managers and their investors. ZEDRA’s full range of services is designed to preserve and protect the real value of clients’ assets and support them in unlocking growth and expansion.
Raja Hadji-Touma and Derrick Estes, Managing Directors at Corsair Capital said, “ZEDRA is a unique firm with unparalleled capabilities, and we are pleased to have closed this exciting investment. We look forward to partnering with an ambitious management team, led by Bart Deconinck, with a proven track record of building leading companies in the sector. We believe our investment and financial services expertise, along with the unmatched global network we bring to bear, will help support continued rapid growth at ZEDRA.”
Over the last 12 months, ZEDRA has made a number of important acquisitions, creating an expanded platform with over 570 staff in a 16 office network covering 13 jurisdictions across Asia, Oceania, the Americas and Europe. As the Company continues to integrate these acquisitions, ZEDRA is even better-placed to continue creating and delivering bespoke trust, corporate and fund services solutions for clients including high-net-worth individuals and their families, international corporations, institutional investors and entrepreneurs.
Bart Deconinck, Group Executive Chairman added, “Today marks the start of the next stage of ZEDRA‘s ambitious growth plans. Powered by a combination of the resources and expertise of Corsair, together with ZEDRA’s considerable experience in the sector, we are looking forward to a period of rapid growth and expansion of the range of services we offer to our clients. The major acquisitions we have made over the past year expand our footprint across Switzerland, the Nordic countries, Cayman and offshore UK jurisdictions, bringing additional clients and staff into the ZEDRA family.”
Under its ‘Active - Wealth’ umbrella, ZEDRA provides a single point of contact for the administration of a wide range of assets for families with diversified investments, including the administration of any relevant structures they require, such as their corporate investment ventures, single-family offices, or private funds for various family members.
Ivo Hemelraad commented: “We are delighted to have completed this transaction and to begin our partnership with Corsair Capital. Their commitment and support to ZEDRA’ S growth as well as to our people are an exciting step for ZEDRA to further enhance our offering and position in the industry.”
Editor notes
https://www.zedra.com/boilerplate/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005091/en/
Contact:
Guy Stephenson Nacelle 020 8333 9125
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom